Jurata Thin Film brings new vaccine packaging and storage tech to market

By The Science Advisory Board staff writers

September 29, 2020 -- Jurata Thin Film is bringing its technology, which allows biologics and vaccines to be packaged, shipped, and stored at room temperature for extended periods of time, to market.

MSI-TX Thin Film enables up to 500 doses of a vaccine to be placed on a single wafer-thin 8.5 by 11-inch sheet of film, weighing just one hundredth of a pound. It contains a proprietary surfactant-stabilized cellulose matrix material, which was developed at the University of Texas College of Pharmacy, in Austin, TX. The film allows the same amount of vaccine and other biologics to be delivered at room temperature in less than one percent of packaging volumes than presently required. The technology would remove the need for specialized storage containers and cold storage requirements for biologics.

The film, transfer process, and reconstitution process have been fully tested and are ready for commercial use. Jurata Thin Film, whose formation was spurred by the technology, has spearheaded the research and development of the product.

According to the International Air Transport Association, it is estimated that delivery of one dose of COVID-19 vaccines to the world's 7.8 billion people will require 8,000 jumbo jet cargo planes. With most vaccines under development as a two-dose regimen, this would bring the total requirement to 16,000 jets. According to Maria Croyle, PhD, who is pioneering the technology, MSI-TX Thin Film can deliver the same amount of vaccine around the globe with just four jets.

Thermo Fisher expands plastics production to support COVID-19 efforts
Thermo Fisher Scientific is investing an additional $140 million to further expand its laboratory plastics consumables production to support the...
Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University...
SiO2 increases vial capacity for COVID-19 vaccines
Advanced materials company SiO2 Materials Science has increased the manufacturing capacity of its plastic medical-grade vials to help meet the demand...
Catalent to provide fill-finish for Moderna's COVID-19 vaccine
Catalent will collaborate with Moderna for large-scale commercial fill-finish manufacturing of Moderna's messenger RNA-based COVID-19 vaccine candidate,...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter